本帖最后由 凤凰涅盘 于 2011-11-13 21:20 编辑
Press Releases
Advanced Cell Technology Announces 2011 Third Quarter Results
MARLBOROUGH, Mass. — November 9, 2011 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today third quarter financial results for the period ended September 30, 2011. The Company reported a loss from operations of $(6.9) million compared to a loss from operations of $(5.4) million in the same period a year ago. Net cash used in operations for the 2011 second quarter was $4.1 million, compared to net cash used in operations of $2.5 million in the same period in 2010. The increase in cash used in operations was a result of the clinical activities related to the Company’s Phase I/II trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD). The Company ended the 2011 third quarter with cash and cash equivalents of $13.9 million, compared to $16.1 million as of June 31, 2011.
“We are excited by the developments we have seen to date in patients with SMD and AMD in clinical activities,” said Gary Rabin, Chairman and CEO of ACT. “We believe that these two trials could represent a paradigm shift in the way that stem cells are used to treat patients with unmet medical needs.” The Company will hold a conference call at 4:30 p.m. EDT on Wednesday during which it will discuss third quarter 2011 results and provide a clinical update. Interested parties may dial (888) 264-3177 and reference conference ID number 19849491. The call will be available live and for replay by webcast at:
请大家注意红颜色的文字 |
